Study Boosts Prospects for Pfizer's Chantix
On Thursday, Pfizerannounced the results of a study of the safety and effectiveness of its Chantix smoking-cessation drug on relapsed smokers. The prognosis was good.
Over the course of 12 weeks of treatment, smokers who had used Chantix before and failed to quit, or had quit but subsequently relapsed, were found to benefit from Chantix at "efficacy rates ... consistent with findings seen in other Chantix clinical trials in smokes who had not been previously treated with Chantix."
Translation: It works just as well the second time around.
Safety and tolerability of the drug were similarly found to be "consistent with previous studies," with the most commonly reported side effects being nausea, abnormal dreams, and headaches.
Summarizing the findings, Pfizer senior vice president and medicines development group head Dr. Steven J. Romano was quoted as saying: "These new data show that, for some adult smokers who had previously taken CHANTIX but either did not quit smoking or relapsed after quitting, another quit attempt with CHANTIX may be fruitful."
The article Study Boosts Prospects for Pfizer's Chantix originally appeared on Fool.com.
Fool contributor Rich Smith has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
